Y-Biologics has transferred anti-cancer drug technology

to Pierre Fabre

Y-Biologics announced on the 6th that it has signed a license agreement with French pharmaceutical group Pierre Fabre for antibody candidates.

 

The deal is worth up to 116.4 billion won, including upfront fee and Milestone.

 

Under the deal, Y-Biologics grants Pierre Fabre the right to exclusively develop and commercialize YBL-003, which has been developed for solid cancer treatment purposes worldwide.

 

YBL-003 is a type of Checkpoint inhibitor that controls macrophage function and T-cell activity to reactivate the immune system of the tumor microenvironment and kill cancer cells.

 

It is an early-stage leading material, and milestones can occur whenever the development of YBL-003, such as preclinical and clinical, proceeds and reaches commercialization goals.

 

Technical fees for sales are guaranteed separately.

 

However, detailed contract terms such as initial down payment were not disclosed.

 

Industry sources say that the license contract for YBL-003, which is an early stage of development, could be concluded because the two companies maintained a close cooperative relationship while conducting joint research since last year.

 

They have agreed to study three targets every year and jointly study and transfer up to 15 targets during the contract period.

 

The joint research contract between the two companies is three years, and the contract can be extended for the next two years.

 

YBL-003 is considered highly likely to be used as an immune anticancer drug for solid cancer targets as it can expand its adaptations to stomach, lung and breast cancer.

 

Pierre Fabre plans to develop a new design drug optimized for tumor treatment through preclinical and clinical development after the introduction of YBL-003.

 

This contract is the first of 15 targets, and there is a possibility that additional contracts will be made in the future.

 

Pierre Fabre is the second largest pharmaceutical group in France.

 

Last year's sales amounted to 2.3 billion euros.

 

Recently, while adjusting R&D priorities, it has focused on apothecary fields such as targeted treatment and immuno-tumorology.

 

In addition to colon cancer, breast cancer, lung cancer, and melanoma, it is known that there is a high interest in pre-cancer diseases such as photokeratosis.

 

Y-Biologics is a bio-venture that specializes in developing antibody new drugs based on its own platform.

 

It was founded in 2007 by Dr.

 

Park Young-woo, who has been working on antibody new drugs for 20 years in LG Life Sciences.

 

It is discovering and developing various pipelines based on original technologies such as more than 100 billion kinds of human antibody library "Ymax-ABL" and dual antibody platform "ALiCE".

 

It is currently in the process of listing on KOSDAQ through technical specials within this year.

 

Earlier this year, it passed the screening, receiving A ratings from two professional evaluation agencies designated by the Korea Exchange, and filed a preliminary review of KOSDAQ listing in May.

 

Park Young-woo, CEO of Y-Biologics, said, "I am very happy to sign the first license agreement with Pierre Fabre.

 

As joint research is underway on another innovative target, we expect cooperation between the two companies to further develop innovative immune tumor treatments targeting the tumor microenvironment."